Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

NCT06177301 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

266

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Tislelizumab combined with GX
DRUG: Tislelizumab combined with GP

Sponsor

Fudan University